Agenus Inc - May 5, 2023 Form 4/A - Amendment Insider Report for MiNK Therapeutics, Inc. (INKT)

Role: 10%+ Owner
Signature: /s/ Christine Klaskin, Vice President, Finance
Stock symbol: INKT
Transactions as of: May 5, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 5/26/2023, 05:28 PM
Date Of Original Report: May 5, 2023
Previous filing: May 5, 2023
Next filing: May 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	INKT	Common Stock						21.5M	May 5, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On May 5, 2023, Agenus Inc. ("Agenus") disclosed a transaction involving 100,000 Mink Therapeutics shares. It agreed to purchase such shares from Garo Armen, the CEO and Chairman of Agenus, at Dr. Armen's original purchase price, which was lower than the market price at the time of the proposed purchase. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the Mink Therapeutics shares were returned to Dr. Armen, and the purchase price was given back to Agenus. This amendment accounts for the changes in Agenus' ownership following the reversal of this transaction.

Content

On May 5, 2023, Agenus Inc. ("Agenus") disclosed a transaction involving 100,000 Mink Therapeutics shares. It agreed to purchase such shares from Garo Armen, the CEO and Chairman of Agenus, at Dr. Armen's original purchase price, which was lower than the market price at the time of the proposed purchase. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the Mink Therapeutics shares were returned to Dr. Armen, and the purchase price was given back to Agenus. This amendment accounts for the changes in Agenus' ownership following the reversal of this transaction.